AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
44 hedge funds and large institutions have $25.7M invested in AVEO Pharmaceuticals, Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 48 → 44 (-4)
10% less capital invested
Capital invested by funds: $28.5M → $25.7M (-$2.81M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$179K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$40.8K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$18K |
| 4 |
Goldman Sachs
New York
|
+$15.9K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$498K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$249K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$92K |
| 4 |
SIM
Spark Investment Management
New York
|
-$56.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$47K |
AVEO Hedge Fund Activity: Q3 2016 in Review
44 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2016, worth a combined $25.7M — down 9.9% from $28.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of AVEO and 6 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $179K. The largest seller was Nexthera Capital, exiting entirely with an estimated $498K sold.
- 44 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2016, down from 48 in Q2 2016.
- Funds reported $25.7M of AVEO Pharmaceuticals, Inc. stock for Q3 2016, down 9.9% quarter-over-quarter.
- 6 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2016 and 10 closed out, a net change of -4 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2016 was Renaissance Technologies, an estimated $179K added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2016 was Nexthera Capital, an estimated $498K sold.
Based on aggregated 13F filings for Q3 2016.